Neoadjuvant chemotherapy with gemcitabine and s-1 for resectable and borderline pancreatic ductal adenocarcinoma: Results from a prospective multi-institutional phase 2 trial

Fuyuhiko Motoi, Kazuyuki Ishida, Fumiyoshi Fujishima, Shigeru Ottomo, Masaya Oikawa, Takaho Okada, Hiromune Shimamura, Shinichi Takemura, Fuminori Ono, Masanori Akada, Kei Nakagawa, Yu Katayose, Shinichi Egawa, Michiaki Unno

研究成果: Article

81 引用 (Scopus)

抜粋

Background: Surgical resection is the only curative strategy for pancreatic ductal adenocarcinoma (PDAC), but recurrence rates are high even after purported curative resection. First-line treatment with gemcitabine and S-1 (GS) is associated with promising antitumor activity with a high response rate. The aim of this study was to assess the feasibility and efficacy of GS in the neoadjuvant setting. Methods: In a multi-institutional single-arm phase 2 study, neoadjuvant chemotherapy (NAC) with gemcitabine and S-1, repeated every 21 days, was administered for two cycles (NAC-GS) to patients with resectable and borderline PDAC. The primary end point was the 2-year survival rate. Secondary end points were feasibility, resection rate, pathological effect, recurrence-free survival, and tumor marker status. Results: Of 36 patients enrolled, 35 were eligible for this clinical trial conducted between 2008 and 2010. The most common toxicity was neutropenia in response to 90 % of the relative dose intensity. Responses to NAC included radiological tumor shrinkage (69 %) and decreases in CA19-9 levels (89 %). R0 resection was performed for 87 % in resection, and the morbidity rate (40 %) was acceptable. The 2-year survival rate of the total cohort was 45.7 %. Patients who underwent resection without metastases after NAC-GS (n = 27) had an increased median overall survival (34.7 months) compared with those who did not undergo resection (P = 0.0017). Conclusions: NAC-GS was well tolerated and safe when used in a multi-institutional setting. The R0 resection rate and the 2-year survival rate analysis are encouraging for patients with resectable and borderline PDAC.

元の言語English
ページ(範囲)3794-3801
ページ数8
ジャーナルAnnals of Surgical Oncology
20
発行部数12
DOI
出版物ステータスPublished - 2013 11 1

ASJC Scopus subject areas

  • Surgery
  • Oncology

フィンガープリント Neoadjuvant chemotherapy with gemcitabine and s-1 for resectable and borderline pancreatic ductal adenocarcinoma: Results from a prospective multi-institutional phase 2 trial' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用